Yes, Dupixent (dupilumab) is a specialty drug. It’s a biologic medication that requires refrigerated storage, is self-injected rather than taken as a pill, and typically costs tens of thousands of dollars per year. Most insurance plans route it through a specialty pharmacy rather than your local drugstore, and getting coverage almost always involves prior authorization.
What Makes Dupixent a Specialty Drug
Specialty drugs are medications that treat complex or chronic conditions and come with requirements that set them apart from standard prescriptions. Dupixent checks every box. It’s a biologic, meaning it’s made from living cells rather than synthesized chemically like most pills. It must be stored in a refrigerator between 36°F and 46°F and can only survive at room temperature for up to 14 days before it needs to be thrown away. You inject it under the skin on a recurring schedule, and the ongoing cost puts it firmly in specialty territory.
These characteristics matter because they change how you get the drug. Standard medications go through retail pharmacies with minimal friction. Specialty drugs like Dupixent often require a designated specialty pharmacy that can handle cold-chain shipping, coordinate with your insurance, and provide clinical support. Your insurance plan usually dictates which specialty pharmacy you must use, so you may not get to choose. In some cases, a retail pharmacy can order and dispense specialty medications, but this is the exception rather than the rule.
What Dupixent Treats
Dupixent works by blocking a specific immune signaling pathway involved in inflammation. The FDA has approved it for six conditions:
- Atopic dermatitis (eczema) in patients 6 months and older with moderate-to-severe disease that hasn’t responded well to topical treatments
- Asthma in patients 6 and older with moderate-to-severe symptoms driven by a specific type of immune cell (eosinophils) or who depend on oral steroids
- Chronic rhinosinusitis with nasal polyps in patients 12 and older whose condition isn’t adequately controlled
- Eosinophilic esophagitis in patients 1 year and older weighing at least 15 kg
- Prurigo nodularis in adults
- Chronic obstructive pulmonary disease (COPD) in adults with eosinophil-driven disease that isn’t well controlled
The drug is co-developed and marketed by Regeneron and Sanofi, two pharmaceutical companies that have a long-standing collaboration agreement. Regeneron co-commercializes Dupixent in the United States and in certain countries outside the U.S.
How Insurance Coverage Works
Because Dupixent is a specialty drug, getting insurance to pay for it involves more steps than a typical prescription. Prior authorization is standard across nearly all plans, meaning your doctor must submit documentation proving you need it before your insurer agrees to cover it.
For atopic dermatitis, insurers like Aetna require chart notes showing the affected areas, the body surface area involved, and evidence that you’ve already tried and failed other treatments (often topical steroids or other prescription therapies). If those treatments aren’t advisable for you, your doctor needs to document why. For nasal polyps, insurers may require endoscopy or CT scan results along with records of previous medications tried. Continuation of coverage after the initial approval period requires documentation that the drug is actually working for you, such as reduced symptoms or lower disease activity.
This process, sometimes called step therapy, means you generally can’t start on Dupixent as a first-line treatment. Your insurer wants to see that less expensive options were tried first. The specifics vary by plan, but expect paperwork and possible back-and-forth between your doctor’s office and your insurance company before you fill your first prescription.
Cost and Financial Assistance
Dupixent is expensive, which is typical of biologic specialty drugs. Your actual out-of-pocket cost depends heavily on your insurance plan’s formulary tier and benefit structure, but the sticker price without any coverage runs into the tens of thousands annually.
The manufacturer offers a program called Dupixent MyWay that can significantly reduce what you pay. If you have commercial insurance, the MyWay copay card may bring your out-of-pocket cost to $0, with an annual benefit cap of $13,000. To qualify, you need commercial insurance, a valid prescription for an FDA-approved use, and you must be 18 or older (or have a caregiver who is). Patients whose prescriptions are covered by government programs like Medicare, Medicaid, Veterans Affairs, TRICARE, or Department of Defense plans are not eligible for the copay card.
For people who are uninsured or have very limited coverage, the Dupixent MyWay Patient Assistance Program may provide the medication for free. Eligibility requires an adjusted gross income at or below $100,000 for individuals, along with detailed financial documentation and physician enrollment. Approvals last one year and need to be renewed annually. Beyond these manufacturer programs, state pharmaceutical assistance programs, disease-specific foundations, and hospital charity care programs may also help depending on your situation.
What to Expect at the Pharmacy
Once your insurance approves coverage, your specialty pharmacy will coordinate shipment. Dupixent arrives in temperature-controlled packaging because it must stay refrigerated. You’ll store it in your refrigerator at home until you’re ready to inject. Before each injection, you can let the syringe or pre-filled pen warm to room temperature, but once it’s been out of the fridge for more than 14 days, it’s no longer usable.
Most specialty pharmacies assign you a care coordinator who handles refill scheduling, checks in on how treatment is going, and helps navigate any insurance reauthorization when your approval period runs out. This level of support is one of the defining features of the specialty pharmacy model, and it’s a practical benefit given how much paperwork biologics tend to involve.